Pluvicto: Most Asked Questions
January 22, 2024
Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy
February 7, 2024
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) is a rare, progressive, and often fatal genetic disease caused by mutations in the transthyretin (TTR) gene. It results in the accumulation of amyloid fibrils in the nerves, heart, and other organs, leading to symptoms such as polyneuropathy and cardiomyopathy, as well as other serious complications.
Understanding Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
What is hereditary transthyretin-mediated amyloid polyneuropathy?
Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) is a rare, inherited condition characterized by the abnormal buildup of amyloid deposits in various parts of the body, primarily affecting the peripheral nerves and heart. The accumulation of amyloid fibrils in these tissues disrupts their normal function, leading to debilitating symptoms and, in severe cases, organ failure.
Understanding the impact of ATTRv-PN
The impact of ATTRv-PN can be devastating, as it can significantly impair a person’s quality of life and lead to life-threatening complications. Symptoms often include progressive sensory, motor, and autonomic neuropathy, as well as cardiac abnormalities, which can ultimately result in heart failure and other serious cardiac conditions.
Current treatment options for hereditary transthyretin-mediated amyloid polyneuropathy
Until recently, treatment options for hereditary transthyretin-mediated amyloid polyneuropathy were limited and focused primarily on managing symptoms and slowing disease progression. However, with the introduction of new therapeutic approaches, such as eplontersen, there is hope for more effective interventions that can potentially modify the course of the disease and improve patient outcomes.
Eplontersen and Its Role in Managing ATTRv-PN
Eplontersen, an antisense oligonucleotide developed by Ionis Pharmaceuticals, has shown promising potential in managing the symptoms and disease progression of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN). Its mechanism of action targets the TTR protein, aiming to reduce the production of amyloid fibrils and alleviate the neuropathic and cardiac manifestations associated with the condition.
Overview of Eplontersen
Eplontersen is designed to specifically address the underlying cause of hereditary transthyretin amyloidosis by modulating the expression of the TTR gene. By binding to the TTR mRNA, eplontersen inhibits the translation of the pathogenic protein, leading to a reduction in amyloid deposition and potentially slowing the progression of neuropathy and cardiomyopathy.
Results from the Neuro-ttransform Phase III Trial
The phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy assessed the efficacy and safety of eplontersen in patients with ATTRv-PN. The trial demonstrated positive outcomes in the co-primary endpoints, including the Neuropathy Impairment Score + 7 (mNIS+7) and the Norfolk QOL-DN, indicating improvements in neuropathic symptoms and quality of life for patients receiving eplontersen compared to the external placebo group. These findings suggest the potential of eplontersen to address the unmet medical needs of individuals with ATTRv-PN.
Interim Analysis of Eplontersen’s Effectiveness
An interim analysis of the phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy revealed promising efficacy and safety of eplontersen in patients with ATTRv-PN. The results may support the regulatory approval of eplontersen as a therapeutic option for managing this debilitating condition. Eplontersen may offer hope for improving the outcomes and quality of life of individuals affected by hereditary transthyretin amyloidosis, paving the way for a more targeted and effective approach to addressing amyloid cardiomyopathy and polyneuropathy associated with ATTRv-PN.
Exploring the Benefits and Risks of Eplontersen
Eplontersen offers potential benefits for patients with ATTRv-PN, addressing the underlying cause of hereditary transthyretin amyloidosis. By targeting the TTR protein, eplontersen aims to reduce the production of amyloid fibrils, which may alleviate the neuropathic and cardiac manifestations associated with the condition. The results from the phase III trial have shown promising efficacy and safety of eplontersen, indicating improvements in neuropathic symptoms and quality of life for patients receiving the treatment.
Potential benefits of eplontersen for ATTRv-PN patients
For individuals with ATTRv-PN, eplontersen holds the potential to modify the disease progression by reducing amyloid deposition and slowing the advancement of neuropathy and cardiomyopathy. The interim analysis of the phase III trial revealed positive outcomes, supporting the regulatory approval of eplontersen as a therapeutic option for managing this debilitating condition. Overall, eplontersen may offer hope for improving the outcomes and quality of life of individuals affected by hereditary transthyretin amyloidosis, representing a promising advancement in the field of amyloid cardiomyopathy and polyneuropathy treatment.
Side effects and safety profile of eplontersen
As with any pharmaceutical intervention, the safety profile of eplontersen in patients with ATTRv-PN is an essential consideration. While the phase III trial has shown promising results in terms of efficacy, further evaluation of the long-term safety and potential adverse effects of eplontersen is necessary. Monitoring for any adverse reactions and assessing the treatment’s overall tolerability will be crucial in determining its suitability for widespread clinical use.
The Future of Eplontersen in ATTRv-PN Treatment
The potential impact of eplontersen on managing ATTRv-PN holds promise for addressing the underlying cause of hereditary transthyretin amyloidosis and modifying the disease progression. By targeting the TTR protein, eplontersen aims to reduce amyloid deposition, potentially slowing the advancement of neuropathy and cardiomyopathy in ATTRv-PN patients.
Looking ahead: Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy
The ongoing phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy is crucial in assessing the efficacy and safety of eplontersen in patients with ATTRv-PN. Positive outcomes from the trial may lead to regulatory approval for eplontersen, offering hope for individuals affected by hereditary transthyretin amyloidosis and representing a significant advancement in the management of amyloid cardiomyopathy and polyneuropathy associated with ATTRv-PN.
Quiz The information you’ve just read!
References
1. AstraZeneca [Internet]. Press release. Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) [last accessed 16 March 2023]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints.html.
2. Dyck P, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. J Neurol Sci. 2019 Oct 15;405:116424.
3. Cortese A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.J Neurol Neurosurg Psychiatry. 2017;88(5):457-458.
4. Ionis Pharmaceuticals [Internet]. Press release. Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) [last accessed 16 March 2023]. Available from: https://ir.ionispharma.com/news-releases/news-release-details/ionis-announces-fda-acceptance-new-drug-application-eplontersen.
5. Viney N, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure. 2020; 8:652-661.
6. Coelho T, et al. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Neurol Ther 12, 267–287 (2023).
7. Columbia University Irving Medical Center [Internet]. Drug Reduces Death from Underdiagnosed Form of Heart Failure [last accessed 22 March 2023]. Available from: https://www.cuimc.columbia.edu/news/drug-reduces-deaths-underdiagnosed-form-heart-failure.
8. Rintell D, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16:70.
9. Ionis Pharmaceuticals [Internet]. Annual Report, 2022 [last accessed 16 March 2023]. Available from: https://ir.ionispharma.com/static-files/db9dff5d-8683-485a-a517-15e264fe7532.
10. Coelho T, et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx(ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.Neurol Ther. 2021 Jun;10(1):375-389.
